Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Bannwarth

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Drug Safety|January 22, 2003
Hospital visits caused by adverse drug reactions: incidence and preventability assessed in French primary care/emergency departmentsBernard Bannwarth, Patrice Queneau, Françoise Carpentier, et al.
Rheumatology (Oxford, England)|August 14, 2015
Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceThierry Schaeverbeke, Marie-Elise Truchetet, Marie Kostine, et al.
Drug Safety|December 24, 2002
Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patientsBernard Bannwarth, Richard Trèves, Liana Euller-Ziegler, et al.
The Journal of Rheumatology|June 9, 2005
A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back painBernard Bannwarth, François-Andre Allaert, Bernard Avouac, et al.
Joint Bone Spine|September 30, 2008
Fibromyalgia syndrome in the general population of France: a prevalence studyBernard Bannwarth, Francis Blotman, Katell Roué-Le Lay, et al.
Bulletin De L'Academie Nationale De Medecine|October 15, 2003
[Adverse drug effects observed at French admissions departments and emergency services (Prospective study of the National Educational Association for Teaching Therapeutics and proposals for preventive measures]Patrice Queneau, Bernard Bannwarth, Françoise Carpentier, et al.
Therapie|July 10, 2016
[Not Available]Albert Trinh-Duc, Jean Doucet, Bernard Bannwarth, et al.
Therapie|January 22, 2008
[Admissions of elderly to French emergency departments related to adverse drug events]Albert Trinh-Duc, Jean Doucet, Bernard Bannwarth, et al.
Arthritis Research & Therapy|April 1, 2016
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registryMarie-Elise Truchetet, Nicolas Poursac, Thomas Barnetche, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 13, 2006
Molecular lipophilicity determination of a huperzine series by HPLC: comparison of C18 and IAM stationary phasesFrançois Darrouzain, Philippe Dallet, Jean-Pierre Dubost, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Drug Safety|January 22, 2003
Hospital visits caused by adverse drug reactions: incidence and preventability assessed in French primary care/emergency departmentsBernard Bannwarth, Patrice Queneau, Françoise Carpentier, et al.
Rheumatology (Oxford, England)|August 14, 2015
Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceThierry Schaeverbeke, Marie-Elise Truchetet, Marie Kostine, et al.
Drug Safety|December 24, 2002
Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patientsBernard Bannwarth, Richard Trèves, Liana Euller-Ziegler, et al.
The Journal of Rheumatology|June 9, 2005
A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back painBernard Bannwarth, François-Andre Allaert, Bernard Avouac, et al.
Joint Bone Spine|September 30, 2008
Fibromyalgia syndrome in the general population of France: a prevalence studyBernard Bannwarth, Francis Blotman, Katell Roué-Le Lay, et al.
Bulletin De L'Academie Nationale De Medecine|October 15, 2003
[Adverse drug effects observed at French admissions departments and emergency services (Prospective study of the National Educational Association for Teaching Therapeutics and proposals for preventive measures]Patrice Queneau, Bernard Bannwarth, Françoise Carpentier, et al.
Therapie|July 10, 2016
[Not Available]Albert Trinh-Duc, Jean Doucet, Bernard Bannwarth, et al.
Therapie|January 22, 2008
[Admissions of elderly to French emergency departments related to adverse drug events]Albert Trinh-Duc, Jean Doucet, Bernard Bannwarth, et al.
Arthritis Research & Therapy|April 1, 2016
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registryMarie-Elise Truchetet, Nicolas Poursac, Thomas Barnetche, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 13, 2006
Molecular lipophilicity determination of a huperzine series by HPLC: comparison of C18 and IAM stationary phasesFrançois Darrouzain, Philippe Dallet, Jean-Pierre Dubost, et al.
Pageof 6